Publisher
Japanese Society on Thrombosis and Hemostasis
Reference33 articles.
1. 1) Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, Hill FG, Hay CR; UK Haemophilia Centre Doctors’ Organisation: The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2: 1047–1054, 2004.
2. 4) White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee: Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.Thromb Haemost 85: 560, 2001.
3. 6) Inoue T, Shima M, Takeyama M, Matsumoto T, Nishiya K, Tanaka I, Sakurai Y, Giddings JC, Yoshioka A: Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 12: 110–113, 2006.
4. 7) Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343: 457–462, 2000.
5. 8) Yoshioka A, Kamisue S, Tanaka I, Kato M, Kohmura I, Shima M, Fukui H: Anamnestic response following infusion of prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (aPCC) in haemophilia A Patients with inhibitors. Blood coagul Fibrinolysis 2: 51–58, 1991.